Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer.

Anna Tankiewicz-KwedloJustyna Magdalena HermanowiczTomasz DomaniewskiKrystyna PawlakMałgorzata RusakAnna PryczyniczArkadiusz SurazynskiTomasz KaminskiAdam KazberukDariusz Pawlak

Published in: British journal of pharmacology (2018)

Epo significantly enhances the antitumour activity of LFM-A13, indicating that a combination of Epo and LFM-A13 has potential as an effective therapeutic approach for patients with colorectal cancer.

Keyphrases

risk assessment
human health
recombinant human